Royce & Associates LP acquired a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 57,500 shares of the biotechnology company’s stock, valued at approximately $796,000.

Other institutional investors have also bought and sold shares of the company. Wells Fargo & Company MN boosted its stake in shares of Heron Therapeutics by 78.8% during the 1st quarter. Wells Fargo & Company MN now owns 39,579 shares of the biotechnology company’s stock worth $595,000 after buying an additional 17,442 shares during the last quarter. FMR LLC boosted its stake in shares of Heron Therapeutics by 36.7% during the 1st quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Heron Therapeutics during the 1st quarter worth about $2,002,000. Tang Capital Management LLC boosted its stake in shares of Heron Therapeutics by 39.7% during the 1st quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares during the last quarter. Finally, Swiss National Bank boosted its stake in shares of Heron Therapeutics by 39.9% during the 1st quarter. Swiss National Bank now owns 72,600 shares of the biotechnology company’s stock worth $1,089,000 after buying an additional 20,700 shares during the last quarter.

A number of equities analysts have recently commented on the stock. BidaskClub downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Noble Financial reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Thursday, August 10th. Cantor Fitzgerald set a $31.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Friday, August 18th. Jefferies Group LLC reiterated a “buy” rating on shares of Heron Therapeutics in a research note on Wednesday, August 16th. Finally, Cowen and Company set a $40.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $29.25.

WARNING: “Royce & Associates LP Takes Position in Heron Therapeutics, Inc. (HRTX)” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://www.watchlistnews.com/royce-associates-lp-takes-position-in-heron-therapeutics-inc-hrtx/1570186.html.

Shares of Heron Therapeutics, Inc. (NASDAQ HRTX) opened at 15.40 on Monday. Heron Therapeutics, Inc. has a 52 week low of $12.21 and a 52 week high of $20.85. The firm’s market capitalization is $833.73 million. The company has a 50-day moving average of $15.87 and a 200 day moving average of $14.95.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to analysts’ expectations of $4.53 million. Equities research analysts anticipate that Heron Therapeutics, Inc. will post ($3.51) earnings per share for the current year.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics, Inc. (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.